Eugit Therapeutics

Active

Enabling Tissue Targeting of Therapies

Summer 2022Founded 20222 peopleSan Francisco, CA, USA; South San Francisco, CA, USA

About

Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).

Founders · 1

Nizar BatadaFounder

Stanford🎓 University of Edinburgh

Nizar is the co-founder and CEO at EUGIT, which he started with George Church in 2022. He is an expert in cancer research, genomics and bioinformatics and has published over 25 articles in peer-reviewed journals such as Nature and has obtained nationally competitive grants. Prior to EUGIT, he was a scientist at 23andMe and a tenure track lecturer at the University of Edinburgh, UK. Nizar grew up in Toronto and obtained his PhD in Biophysics from Stanford.

LinkedIn ↗

Launch

Launched on Y Combinator · Jul 2022

View launch post ↗

Engineered gamma delta T-cells for off-the-shelf treatment of cancers

EUGIT Therapeutics develops off-the-shelf engineered gamma delta T cells to treat breast, ovarian, and prostate cancers, aiming to provide ready-to-infuse immune cell therapy. The company’s approach uses donor-derived gamma delta T cells gene-engineered to fight cancer, targeting cancers where existing immunotherapies have limited success.

From the original launch (Jul 2022) — may be outdated.

Formerly “EUGIT Tx”, “EUGIT Therapeutics”, “Eugit”, “Eugit Therapeutics Inc”